Table 1.

Baseline distribution of moderators in patients with lymphoma in Edmonton, Canada, 2005–2008

VariableOverall (n = 117)UC (n = 60)AET (n = 57)P
Age0.839
 <50 y38 (32.5)20 (33.3)18 (31.6)
 ≥50 y79 (67.5)40 (66.7)39 (68.4)
Sex0.603
 Male69 (59.0)34 (56.7)35 (61.4)
 Female48 (41.0)26 (43.3)22 (38.6)
Baseline exercise0.206
 Not meeting guidelines84 (71.8)40 (66.7)44 (77.2)
 Meeting guidelines33 (28.2)20 (33.3)13 (22.8)
BMI0.558
 Nonobese85 (72.6)45 (75.0)40 (70.2)
 Obese32 (27.4)15 (25.0)17 (29.8)
Type of lymphoma0.994
 NHL aggressive49 (41.9)25 (41.7)24 (42.1)
 NHL indolent47 (40.2)24 (40.0)23 (40.4)
 HL21 (17.9)11 (18.3)10 (17.5)
Disease stage at study entry0.723
 No evidence of disease32 (27.4)17 (28.3)15 (26.3)
 Stage I/II40 (34.2)22 (36.7)18 (31.6)
 Stage III/IV45 (38.5)21 (35.0)24 (42.1)
Current treatment status0.661
 Off-treatment64 (54.7)34 (56.7)30 (52.6)
 Receiving chemotherapy53 (45.3)26 (43.3)27 (47.4)
Time since diagnosis0.954
 <2 y66 (56.4)34 (56.7)32 (56.1)
 ≥2 y51 (43.6)26 (43.3)25 (43.9)
Baseline sleep qualitya0.021
 Poor sleepers55 (47.0)22 (36.7)33 (57.9)
 Good sleepers62 (53.0)38 (63.3)24 (42.1)

NOTE: All values are expressed as n (%).

  • aBased on global sleep quality score of ≥4.3.